Lupus erythematosus
☆ I le 2022 Stiftung Warentest i'uga mai Siamani, o le fa'amalieina o tagata fa'atau i ModelDerm sa na'o sina maualalo ifo nai lo fa'atalanoaga telemedicine totogi.
E foliga mai o se erythema teisi violē.
Le mageso o le pepe e masani ona aliali i luga o foliga.
References
Fa'ailoa ma fa'avasega le cutaneous lupus erythematosus (CLE) o lo'o tula'i mai ai ni lu'itau fa'ata'ita'i, fa'ailogaina mai le systemic lupus erythematosus fa'atasi ai ma le pa'u. O suʻesuʻega talu ai nei na faʻamalamalamaina ai mea faʻapitoa, siosiomaga, ma faʻamaʻi puipuia o loʻo faʻavaeina CLE. O le fa'aosoina o vaila'au fa'apitoa ua tula'i mai o se tasi o mea sili ona taua mo le CLE. Togafitiga e aofia ai togafitiga faʻapitoa ma faʻaogaina, e aofia ai meaola faʻamaonia (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , faʻatasi ai ma le faʻaalia o le aoga i suʻega faʻapitoa.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) e aofia ai fa'afitauli eseese o le pa'u, o nisi o ia mea e ono feso'ota'i atu i fa'afitauli lautele o le soifua maloloina. Ua fa'avasegaina i ituaiga eseese, pei ole acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . O le CCLE e aofia ai le discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus o se vaega o faʻamaʻi autoimmune e mafai ona afaina ai vaega eseese o le tino. O nisi ituaiga, pei o le systemic lupus erythematosus (SLE) , e a'afia ai totoga e tele, a'o isi, pei o le cutaneous lupus erythematosus (CLE) , e a'afia tele ai le pa'u. Matou te fa'avasegaina ituaiga eseese o CLE e fa'atatau i le fefiloi o fa'ailoga fa'apitoa, su'esu'ega a le tino, ma su'ega toto, ae e tele naua suiga i le va o tagata ta'ito'atasi. E masani ona tupu faʻafitauli o le paʻu ona o mea e pei o le faʻaalia o le la, ulaula, poʻo nisi vailaʻau.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Ole mafua'aga ole lupus erythematosus e le o manino. Faatasi ai ma masaga tutusa, afai e afaina le tasi e 24% le avanoa o le a faapena foi le isi. O hormones faʻafeusuaiga fafine, susulu o le la, ulaula, faʻaletonu vitamini D, ma nisi faʻamaʻi pipisi e talitonuina foi e faʻateleina ai le lamatiaga.
Togafitiga e mafai ona aofia ai NSAIDs, corticosteroids, immunosuppressants, hydroxychloroquine, ma methotrexate. E ui lava e aoga corticosteroids, o le faʻaaogaina umi e maua ai aʻafiaga.